Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab

Introduction: Enfortumab vedotin (EV) combined with pembrolizumab (EV+P) is a promising first-line therapy for metastatic urothelial carcinoma. While it has shown significant efficacy, severe cutaneous adverse events such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have be...

詳細記述

書誌詳細

出版年:	European Journal of Case Reports in Internal Medicine
主要な著者:	Benjamin Müller, Riccardo Curatolo, Hazem Juratli, Almir Husic, Josephine Nehring, Eliska Potlukova, Angela Kohler
フォーマット:	論文
言語:	英語
出版事項:	SMC MEDIA SRL 2024-11-01
主題:	enfortumab vedotin pembrolizumab stevens-johnson syndrome (sjs) toxic epidermal necrolysis (ten) cutaneous toxicity
オンライン･アクセス:	https://www.ejcrim.com/index.php/EJCRIM/article/view/5003